drugset / Trial / NCT05172440
A Study on the Safety and Effectiveness of Tislelizumab Combined With Axitinib for Neoadjuvant Treatment of ccRCC
NaSingle-groupOpen-labelTreatment
Summary
This trial is a single-center clinical trial to evaluate the tumor shrinkage and safety of tislelizumab combined with axitinib in Neoadjuvant therapy of T2-T3N0M0 renal clear cell carcinoma
Timeline
- Start
- 2021-12-09
- Primary completion
- 2023-11-20
- Completion
- 2024-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Axitinib | Small molecule | 5 mg | — |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |
Indications
No indication recorded.